University of Saskatchewan
Bioequivalence of highly variable drugs and drug products reviewed
Published in Pharma Law Weekly, November 29th, 2005
According to a recent report from Canada, "'Highly variable drugs' have been defined as those drugs for which the within-subject variability (WSV) equals or exceeds 30% of the maximum concentration (Cmax ) and/or the area under the concentration versus time curve (AUC). Despite the fact that highly variable drugs are generally safe with flat dose response curves, the bioequivalence of their formulations is a problem because the high variability means that large numbers of subjects are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-11-29)
More Articles from Pharma Law Weekly
- Bionomics
Vascular targeting agent developer granted patent for anticancer compounds - Cardinal Health, Inc.
Ivan K. Fong named chief legal officer at pharmaceutical, medical supply company - Center for Information & Study on Clinical Resea
Media coverage of prescription drug safety deters clinical trial participation - Cobalis Corp.
PreHistin to be granted European Union patent - Dynavax Technologies Corp.
Nancy L. Buc, former U.S. FDA chief counsel, joins board of directors - Endocyte, Inc.
Biotech company receives notice of a U.S. patent allowance for targeted immunotherapy - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
